IDH1 and central nervous system cancer: While isocitrate dehydrogenase 1 (IDH1) mutations are present in 70% of lower-grade gliomas and secondary glioblastomas (18–20), and predict better patient survival, whether combined IDH1 mutation status and anatomical tumor-SVZ distance would facilitate more accurate prediction of prognosis has not yet been investigated.